ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testingThis is an addendum to the article available online at https://doi.org/10.1038/gim.2012.165 .
Correction: Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testingAn amendment to this paper has been published and can be accessed via a link at the top of the paper.
ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testingMTHFR polymorphism testing is frequently ordered by physicians as part of the clinical evaluation for thrombophilia. It was previously hypothesized that reduced enzyme activity of MTHFR led to mild hyperhomocysteinemia which led to an increased risk for venous thromboembolism, coronary heart disease, and recurrent pregnancy loss. Recent meta-analyses have disproven an association between hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism.